SAN DIEGO–(BUSINESS WIRE)–Genome Insight, a cancer whole genome platform company, is launching a pilot program in Ajou University Medical Center to test the use of Whole Genome Sequencing (WGS) in routine cancer care setting. Cancer patients at various stages in the treatment journey will be eligible to receive WGS testing if the clinician notices potential … [Read more…]
Clinical Expertise and Advanced Therapies Cater to Growing Patient Population HOUSTON–(BUSINESS WIRE)–#VirtisHealthAmbulatoryInfusionCenters—Virtis Health, a national healthcare provider dedicated to therapeutic and diagnostic services for patients with complex conditions requiring specialty infusible and injectable medications, announced today its unveiling of an ambulatory infusion center (AIC) in Houston. Virtis Health Houston is conveniently located at 6800 West … [Read more…]
— Emerging data reinforce combination lipid-lowering therapy as first-line strategy for very high-risk patients, supporting the development of obicetrapib as adjunct to high-intensity statins — NAARDEN, Netherlands & MIAMI–(BUSINESS WIRE)–NewAmsterdam Pharma (NewAmsterdam Pharma), a clinical-stage company focused on the research and development of transformative oral therapies for metabolic diseases, today announced emerging data adding to … [Read more…]
The study evaluated the effect of the ProAir Digihaler System on asthma control versus standard of care as measured by the Asthma Control Test, and explored use of the ProAir Digihaler System to help support patient-physician interactions for asthma management versus standard of care TEL AVIV, Israel & PARSIPPANY, N.J.–(BUSINESS WIRE)–Teva Pharmaceuticals USA, Inc., a … [Read more…]
SANTA CLARA, Calif.–(BUSINESS WIRE)–#AAA–Shape Memory Medical Inc., developer of custom, proprietary shape memory polymers for the peripheral and neurovascular markets, announced the completion of patient enrollment in AAA-SHAPE, the Company’s prospective, multicenter early feasibility safety study of the IMPEDE-FX RapidFill® Device when used for abdominal aortic aneurysm (AAA) sac management during elective endovascular aneurysm repair … [Read more…]
-TQS-168 demonstrated robust geroprotective effects in preclinical studies- REDWOOD CITY, Calif.–(BUSINESS WIRE)–Tranquis Therapeutics, Inc., a clinical stage immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases, today announced it will present preclinical data on the anti-aging effects of TQS-168, a small molecule modulator of PGC-1a, at ARDD … [Read more…]
-Treatment with Cemdisiran Resulted in a Higher Proportion of Patients Achieving Clinically Meaningful Reductions in 24-Hour Urine Protein to Creatinine Ratio, as Compared to Patients on Placebo – – Consistent Proteinuria Reduction Seen with Secondary Endpoints – – Cemdisiran Was Generally Well-Tolerated in Patients with IgA Nephropathy – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) … [Read more…]
PEARL RIVER, N.Y.–(BUSINESS WIRE)–Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into a license agreement relating to its preclinical asset, Nepicastat, with Asieris Pharmaceuticals, a biotechnology company headquartered in China. Under the terms of the agreement, Acorda will receive an upfront payment of $500,000, and up to an additional $7 million based … [Read more…]
LOS ANGELES–(BUSINESS WIRE)–Levine Leichtman Capital Partners (“LLCP”), a Los Angeles-based private equity firm, announced today that it has sold its portfolio company Monte Nido & Affiliates (“Monte Nido” or the “Company”) to funds managed by Revelstoke Capital Partners LLC. Financial terms of the transaction were not disclosed. Founded in 1996, Monte Nido is a leading … [Read more…]
Q4’22 net revenue of $1.31 billion increased 10% as reported, or 15% in constant currency, compared to Q4’21. Organic, constant-currency net revenue grew 10%, compared to Q4’21. Fiscal 2022 net revenue of $4.83 billion increased 21% as reported, or 23% in constant currency, compared to fiscal 2021. Organic, constant-currency net revenue grew 20% compared to … [Read more…]
